Avacincaptad Pegol
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 80 publications
Real-world retinal vasculitis events reported with FDA-approved intravitreal anti-VEGF and complement inhibitor agents: an analysis of FAERS data.
Journal: Retina (Philadelphia, Pa.)
Published: August 21, 2026
Pharmaceutical Applications of Nucleic Acid Aptamers: Recent Advances and Future Perspectives in Therapeutics, Biosensing, Bioanalysis, and Process Analysis.
Journal: Chemical & pharmaceutical bulletin
Published: August 03, 2026
Examining Real-World Attrition Among Patients Undergoing Complement Inhibitor Intravitreal Therapy for Geographic Atrophy.
Journal: Journal of vitreoretinal diseases
Published: July 31, 2026
Real-World Safety of Intravitreal Complement Inhibitor Avacincaptad Pegol for Geographic Atrophy.
Journal: Journal of vitreoretinal diseases
Published: July 28, 2026
Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy Characterized Using Fundus Autofluorescence: An 18-Month Post Hoc Analysis of GATHER2.
Journal: Investigative ophthalmology & visual science
Published: July 22, 2026
Geographic atrophy: From slowing lesions to preserving vision.
Journal: Current opinion in ophthalmology
Published: May 09, 2026
Comparative Endophthalmitis Rates of Anti-VEGF, Corticosteroid Implants and Anti-Complement Injections: An IRIS® Registry Analysis.
Journal: American journal of ophthalmology
Published: April 30, 2026
ENDOPHTHALMITIS ASSOCIATED WITH INTRAVITREAL INJECTION: Rates, Culture Results, and Visual Acuity Outcomes.
Journal: Retina (Philadelphia, Pa.)
Published: April 16, 2026
Real-world Safety Profile of Avacincaptad Pegol in the Management of Geographic Atrophy.
Journal: Ophthalmic surgery, lasers & imaging retina
Published: March 27, 2026
Off-label intravitreal eculizumab for geographic atrophy: report of the first two cases.
Journal: International journal of retina and vitreous
Published: December 12, 2025
Last Updated: 09/26/2026